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Title:  The drugs don't sell: DIY heart health and the over-the-counter statin experience. 
Abstract  
This paper draws on a study of over-the-counter statins to provide a critical account of 
the figure of the ‘pharmaceutical consumer’ as a key actor in the pharmaceuticalisation 
literature. A low dose statin, promising to reduce cardiovascular risk, was reclassified to 
allow sale in pharmacies in the UK in 2004. We analysed professional and policy debates 
about the new product, promotional and sales information, and interviews with 
consumers and potential consumers conducted between 2008 and 2011, to consider the 
different consumer identities invoked by these diverse actors.  
While policy makers constructed an image of ‘the citizen-consumer’ who would take 
responsibility for heart health through exercising the choice to purchase a drug that was 
effectively rationed on the NHS and medical professionals raised concerns about ‘a 
flawed consumer’ who was likely to misuse the product, both these groups assumed 
that there would be a market for the drug. By contrast, those who bought the product 
or potentially fell within its target market might appear as ‘health consumers’, seeking 
out and paying for different food and lifestyle products and services, including those 
targeting high cholesterol.  However, they were reluctant ‘pharmaceutical consumers’ 
who either preferred to take medication on the advice of a doctor, or sought to 
minimize medicine use.  
In comparison to previous studies, our analysis builds understanding of individual 
consumers in a market, rather than collective action for access to drugs (or, less 
commonly, compensation for adverse effects). Where some theories of 
pharmaceuticalisation have presented consumers as creating pressure for expanding 
markets, our data suggests that sociologists should be cautious about assuming there 
will be demand for new pharmaceutical products, especially those aimed at prevention 
or asymptomatic conditions, even in burgeoning health markets.  
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This paper draws on a study of over-the-counter statins to provide a critical account of 
the figure of the ‘pharmaceutical consumer’ in the UK. Statins, a class of drugs that 
reduces blood cholesterol levels, have been available on prescription since the early 
1990s.  In the UK, as elsewhere, they have become a major part of cardiovascular 
prevention, constituting an important class of prophylactic medication (Greene, 2007).  
Indeed, they have been cited as a textbook case of pharmaceuticalisation, representing 
a rapidly expanding market of drugs for people who do not see themselves as ill 
(Abraham 2010a). In 2004 a low dose statin (10 mg simvastatin) was licensed for sale 
over-the-counter (OTC), that is through pharmacies but without a prescription, in the UK. 
This ‘reclassification’ of statins appeared to open a new site for pharmaceutical 
consumption, allowing both direct to consumer advertising (otherwise impossible in the 
European market) and direct purchase of a significant drug class. Previous and 
subsequent attempts to get similar reclassification in the US failed (Tinetti, 2008), so the 
UK experience was particularly noteworthy; and indeed generated discussion in both 
medicine and social science.  
 
In sociology, a debate about the drivers of the reclassification focussed on the role of 
state or commercial actors in bringing about such deregulation of pharmaceuticals 
(Abraham 2007, Edgely 2007, Moncrieff 2007). In this discussion, not unreasonably, 
there was little reference to consumers, but the contributors apparently assumed that 
there would be a market. Though lay activism and consumerism are described as 
playing a part in the expansion of pharmaceutical use (Abraham 2010b, Bell and Figert 
2012, Williams, Martin and Gabe 2011), there is more to do to understand 
pharmaceutical consumers and consumerism.  
 
Collective consumer action with the aim of gaining access to drugs has received 
attention in the pharmaceuticalisation literature and can draw on sociological studies of 
patient activism, which describe campaigns in relation to the regulation and 
reimbursement of prescription medication for conditions like AIDS or cancer (Epstein 
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1996, Gibbon 2007). Other studies suggest the ways in which commercial companies 
help create such demand through direct marketing as well as clinical research that 
builds awareness of their products and expands indications (e.g. Dumit 2012) and 
through alliances with patient groups (e.g. Moreira 2010). As Abraham (2010b) points 
out however there is also a tradition of activism by those claiming to have been injured 
by pharmaceutical products.  
 
This paper sets out to explore the figure of the individual consumer, as figured in policy, 
marketing and in lay accounts.1 To date, the pharmaceuticalisation literature has drawn 
on cases where drugs come to be accepted as the ‘solution’ to people’s problems, even 
when these are not initially clearly accepted medical conditions. A good example is the 
treatment of anxiety (Williams et al 2011) as well as sexual dysfunction or weight loss 
(e.g. Fishman 2004; Fox, Ward and O’Rourke 2005a; Fox 2006) and products promising 
physical ‘enhancement’ (Williams et al 2011). However lay people’s suspicion of both 
prescription and non-prescription medicines is an established theme in medical 
sociology.  
 
In one review, Pound, Britten, Morgan et al (2005) suggest that while some accept 
pharmaceutical treatment, lay responses to medicine are best characterised by the 
concept of resistance.  This may operate at conceptual and practical levels (Authors, in 
review).  As Pound et al (2005) elaborate, people may be reluctant to take medicines for 
many reasons: concern about side-effects and dependency, the potential disruption of 
regimens to daily routine, a preference for more ‘natural’ therapies, the symbolic 
association of medicines with illness and thus an illness identity, as well as potential 
stigma associated with taking medicines (see also Hansen and Hansen 2006; Norreslet, 
Jemec and Traulsen 2010). At a practical level Pound et al (2005) highlight the way 
people reportedly modify regimens, for example lowering dose or taking ‘drug holidays’, 
as well as demurring to have prescriptions filled, not initiating or discontinuing use. 
While this form of individual or uncoordinated resistance to, or at least ambivalence 
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about medicines has been acknowledged within recent work on pharmaceuticalisation 
(see Williams, Gabe and Martin 2012), it casts some doubt on explanations that focus on 
consumer driven ‘demand’ across a range of drug classes.  
 
The issues that sociologists have identified with resistance are well-known in medicine 
which has its own discourse of the phenomena of non-adherence. For example evidence 
suggests that adherence to prescription statins is low, possibly lower than fifty per cent 
(Benner, Glynn, Mogun et al, 2002; Mantel-Teeuwisse, 2004). The solution there is said 
to lie in better communication between patient and prescriber so that a drug is taken in 
‘concordance’ with a jointly agreed regimen. Yet it has been suggested that patients 
may be making more independent choices, as more reflexive, active approaches to 
healthcare, together with the availability of drugs online, facilitate a ‘consumerist’ 
approach  (Fox et al 2005a; Lupton, Donaldson and Lloyd, 1991. In the case of 
pharmaceuticals, such consumerism has been defined as a situation where ‘healthcare 
consumers perceive pharmaceutical technology as an adjunct in the pursuit of a better 
lifestyle and experience of embodiment’ (Fox et al 2005b, p1482). Here ‘resisting 
consumers’ were those who sought out drugs like Viagra or Orlistat (for weight loss) but 
used them in ways that countered biomedical knowledge, in contrast to ‘expert patients’ 
whose use was in line with professional understanding (Fox 2006).   
 
Other authors have used the language of ‘citizenship’ to view such active approaches to 
healthcare through the lens of political rights and responsibilities. An emerging 
literature using the concept of ‘biological citizenship’ proposes that health and illness 
become central to new identities (Rose and Novas, 2005). Within this framework 
debates about access to drugs are part of the elaboration of the relationship between 
State and individual. In the case of AIDS drugs in Brazil for example, Biehl (2007) has 
argued that people’s claims to treatment alongside marketization helped frame health 
policy around the provision of drugs. However, within this literature, as in 
pharmaceuticalisation, case studies often seem to emphasise the importance of 
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collective consumer action over individual meaning, and do not help explain the co-
existence of both resistance and demand.  
 
In offering our own case study here – telling the story of the OTC statins in the UK – we 
wish to further understanding of the individual pharmaceutical consumer. We draw 
attention to the expectations of consumer demand and ways of imagining the OTC 
statin consumer, as articulated by policy makers and professionals. However we then 
set these expectations against low sales and lay people’s talk about drugs as a 
somewhat problematic product. In looking for different versions of the individual 
consumer in this single case we therefore present data on pharmaceutical ‘consumerism’ 
and reflect on their relevance for theories of pharmaceuticalisation more broadly.  
 
Method  
The paper draws on two parallel projects concerned with cholesterol management, 
designed as comparative cases and carried out consecutively between 2008 and 2011.  
The work was conceived as an exploration of the role of consumer health technologies 
for cholesterol management and their relation to health service provision. The first 
project focussed on functional foods such as spreads, drinks and yoghurts containing 
phytosterols for cholesterol reduction and the second focussed on over-the-counter and 
prescription statins for people at moderate risk of heart disease. We analysed 
professional, policy and marketing discussions around the introduction of these 
technologies and carried out interviews with self-identified 'users'.  Data from both the 
projects turn out to be highly relevant to understanding the story of OTC statins in the 
UK.      
 
In the first study, we interviewed 45 people recruited on the basis that they had bought 
or eaten functional foods containing phytosterols.  In the second study we interviewed 
44 people, recruited on the basis that they had bought or been prescribed a low-dose 
statin. Seven of these had bought the over-the-counter statin, all other respondents 
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from both studies might be thought of as potential OTC statin users.  At the outset it 
was not clear whether users of foods and drugs constituted distinct groups.  In fact, 
there was a great deal of overlap in those we recruited.  Nearly half those using 
phytosterols said they took or had taken statins and those recruited on the basis that 
they had taken a low dose statin also engaged in various dietary practices to manage 
cholesterol.  In a handful of cases this included buying foods containing phytosterols, 
including two in our OTC statin group.  Despite this overlap, in reporting on the 
interviews, respondents are identified according to the project from which they 
originate - Phyt indicates phytosterol project; Stat indicates statin project.   
 
Our respondents were recruited through advertisements in our own universities and the 
newsletters of elders forums and councils in three localities in England. After local 
recruitment proved difficult, users of OTC statins were recruited at a national level, 
using an ad appearing with a Google search for ‘Heart pro’ or ‘Zocor’. Participants were 
chosen from a reasonably large pool of potential recruits to provide diversity on age, 
gender and occupational background. Ages ranged from 24 to 85 years, but most were 
over forty as might be expected (mean=64). Participants had a wide range of 
occupational backgrounds although there was a high proportion with professional and 
managerial backgrounds.  Ethical review was carried out at the authors’ institutions 
before data collection started.  
 
Interviews in study one were conducted by author 2 and by both authors in study two.  
These were conducted in a variety of settings as convenient to the interviewees, 
including in their homes, in the authors' offices and in public spaces such as cafes.  All 
were recorded on digital voice recorders and transcribed.  These were semi-structured 
interviews drawing on a topic guide devised in advance.  Interviews addressed how 
people come to have their cholesterol tested, how they come to be offered or purchase 
a statin or phytosterol food, how they decided whether to start and continue such use, 
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their interactions with health professionals and their wider household practices around 
cholesterol and health. 
 
We also gathered professional, policy and marketing discussions around the 
introduction of the OTC statins. Material was identified through searches of the 
biomedical literature and more general web-based searching to identify relevant policy 
documents, speeches and pharmaceutical marketing from the print media. In addition 
we were able to draw on detailed responses to a consultation on the reclassification of 
statins published by the UK’s Medicines and Healthcare Products Regulatory Agency 
(MHRA), with comment from medical doctors and pharmacists.  
 
Taking these diverse datasets, we undertook an iterative thematic analysis in the way 
proposed by Hammersley and Atkinson (1995) which involved going backwards and 
forwards between the datasets, and specific individuals or documents within them, to 
identify recurrent ideas or narratives about how and why people acquire or do not 
acquire statins. In this paper we first report on the expectations surrounding the 
reclassification of statins and the introduction of the OTC product drawing on policy 
documents, the MHRA consultation and marketing material for the product.  In 
analysing these we are interested in the types of responsibilities, capacities and 
practices ascribed to putative users in these texts and the different versions of 
consumer or patient invoked.  We then turn to the accounts of people who are engaged 
in cholesterol management and focus on the way in which they position themselves as 
acting according to ‘consumer’ or ‘patient’ logics.   Aware that health may have limited 
salience in everyday life (Calnan and Williams, 1991), particularly in an area as prosaic as 
cholesterol management, we did not expect respondents consciously to adopt strong 
and coherent positions or identities in relation to health consumption.  Yet in carrying 
out our analysis we were attuned to different moments during the interviews that were 
suggestive of implicit identity work (McDonald, Mead, Cheraghi-Sohi et al 2007).  
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1. Policy narratives:  giving citizen-consumers choice 
In the UK, national guidelines advise that those at more than 20% risk of cardiovascular 
disease over ten years should be offered prescription statins within the National Health 
Service (NHS) (NICE 2008). This effectively continues a policy of rationing or cost-
containment (Will, 2005).  Initial policy statements about the possibility of 
reclassification emphasised that a new market would allow people ‘at moderate risk’ 
(10-15 percent over 10 years) to access the drugs. John Reid, then Secretary of State for 
Health was quoted in the press release announcing the change:  
“We have already seen a 23% fall in premature death rates from heart disease 
and stroke over the past five years, on line to meet our target of a 40% reduction 
by 2010. This new move will allow more people to protect themselves from the 
risk of coronary heart disease and heart attacks. By extending access to this drug 
we are giving people more choice about how they protect their health. We are 
committed to extending choice whenever advised it is safe to do so...” (MHRA, 
2004)  
 
The extension of the statin market was thus linked in policy discourse to rationales of 
self-care (‘allowing people to protect themselves’) and ‘choice’. These are the hallmarks 
of what has been described (Clarke, Newman, Smith et al, 2007) as the ‘citizen-
consumer’, a key figure in the reform of public services under the New Labour 
government (1997-2010). Such citizen-consumers were encouraged to become ‘fully 
engaged’ in both therapeutic health care and prevention (Wanless, 2002, 2004) taking 
responsibility for their present and future health, and helping manage demand for 
funded services.  
 
While prescribed statins were paid for in the main by the State (a relatively small 
prescription charge is levied with each prescription), it was expected that a new group of 
citizen-consumers would buy the drugs directly, picking up where publicly funded 
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healthcare left off. OTC purchase from pharmacists, who would carry out a minimal risk 
assessment (see Figure 1), was clearly linked to reducing pressure on statutory health 
services (Department of Health 2005) by diverting large numbers of middle aged men 
and women away from their doctor and a prescription. As NHS practice was expected to 
continue as normal, the reclassification therefore embodied a version of consumption 
that was compatible with communitarian logics of making only reasonable demands on 
statutory services (McDonald et al 2007).   
 
FIGURE 1 HERE 
 
The notion of ‘choice’ was not further elaborated in policy. The reclassification proposal 
gave a special role to pharmacists who would carry out the risk assessment and give 
lifestyle advice before selling the drug. This pharmacy-based public health was in 
addition to - not an alternative to - advice on lifestyle change at the population level. 
Within the range of services to be offered by pharmacies, discussions about OTC statins 
appeared alongside advice on smoking cessation and weight loss (Department of Health 
2005). At the level of the individual however extending ‘choice about how they protect 
their health’ appeared to hold out the possibility that people might buy statins instead 
of making changes to lifestyle. This was of great concern to professionals commenting 
on the switch.  
 
2. Professional narratives: flawed consumers in a flawed market 
In examining the figure of the OTC statin consumer from the perspective of healthcare 
professionals we draw on responses to the consultation about the switch, organised by 
the UK’s drug regulators (MHRA, 2003). These responses testify to a wide range of 
different attitudes, within which a slight majority expressed concern about the switch or 
recommended proceeding with caution, in part because of worries about how the 
product would be used.   
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Pharmacists and pharmacy companies were most likely to be supportive of the new 
product, in terms similar to policymakers:  
 
'If this request is granted, patients will have better access to this proven 
medicine and a reduction in deaths from CHD could be expected to follow. The 
‘worried well’ could be taken out of the NHS loop.' (Boots) 
 
‘[The reclassification] gives consumers access to this drug to self medicate where 
they may consider their risk factors are significant.’ (Guild of Healthcare 
Pharmacists) 
 
Though both supportive, these quotes had different implications. While Boots talked of 
‘patients’, the Guild of Healthcare Pharmacists invoked ‘consumers’. Furthermore, 
though Boots described a market among ‘the worried well’ suggesting these were 
people who were unnecessarily anxious about heart health, the second quote 
supported the idea that individuals should act on their own response to risk, a relatively 
abstract notion.  
 
Questions about the cost of the drugs also divided opinion. On one hand some argued 
that if the drugs were beneficial then they should be provided on the NHS to avoid 
excluding people who could not afford the new product. Here OTC statin consumers 
were imagined as a distinct group who could afford the drugs and would therefore 
purchase them. This would have effects on health equity.  
 
‘Patients who can afford to buy the drug will do so, risking a two-tier health 
service in terms of access.’ (Canterbury and Coastal PCT2) 
 
On the other hand it was suggested that rational consumers would ask for prescription 
statins, increasing costs for the NHS:  
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‘It is to be questioned whether the public would continue to take and purchase 
simvastatin over the counter for an indefinite period and whether there would 
be the tendency for the patient once started to request the product on a 
prescription.’ (Exeter PCT) 
 
Here a market was imagined, but it might be short lived if demanding consumers put 
pressure on general practitioners to prescribe and sought to exit the market.  
 
Other clinical concerns also suggested a kind of distrust of users of an OTC product. For 
example, making a choice might mean abandoning behaviour change:  
 
'Patients may choose to use drugs rather than addressing other important 
factors such as diet, or perhaps think they can eat as normal if they take 
medication.' (Pharmacist, New Cross Hospital) 
 
Poor compliance, as with prescription drugs, would leave people at risk and ‘lead to 
consumers developing a false sense of security’ (Southport and Formby PCT). For others, 
there was a risk that enthusiastic consumption of the OTC product would lead to 
dangerous interactions with ‘dietary and nutritional supplements’ (Royal College of 
Physicians).  
 
Many professionals and their organisations, then, rejected the expansion of market 
logics in prevention and the shift from patient to consumer relations that this entailed. 
They suggested that health services are better provided on the basis of rationally 
defined entitlements (citizenship) than (consumer) choices in a marketplace.  In their 
discussions, both users and non-users of over the counter statins were depicted as 
flawed consumers (Bauman 2005): the poorest were excluded altogether, but others 
were expected to make bad choices, taking either too much medication or too little, or 
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choosing to take a pill and abandon healthy lifestyles, either due to lack of information 
or the moral strength to resist easy 'answers in a bottle'. The answer was to continue to 
require a prescription for statin use.  
 
'We feel that the risk benefit ratio of using this drug cannot be properly assessed 
without specialist clinical input.' (Consultant Cardiologist, Royal Wolverhampton 
Hospitals) 
 
3. Marketing narratives: empowered consumers taking control 
Despite the concerns raised by professionals, the reclassification went ahead and a 
10mg statin became available over-the-counter in 2005 under the brand name Zocor 
Heart Pro. Early marketing focussed on the risk of heart disease in relation to age.  Print 
and television adverts started with either a man on his 45th or a woman on her 55th 
birthday, celebrating with champagne, holding a birthday cake or opening a card, who is 
shocked to learn that they now have a one in seven chance of a heart attack (see Figure 
2).  Consumers were presented as highly rational, weighing up the risks they are willing 
to live with and the risks on which they want to take action (1 in 7 is 'a risk too high for 
me' - see Figure 3).  
 
Figures 2 and 3 here 
 
In contrast to the flawed consumers of professional narratives, OTC statin users here 
were portrayed as ordinary, responsible people, doing their best to stay healthy, by 
exercising and trying to eat a balanced diet, but wanting additional ways to 'help protect 
their hearts' (see Figure 3).  These look very similar to the proactive health consumers of 
policy who are making choices to look after themselves and exercise autonomy over 
prevention or ‘take control of their heart health' (see Figure 4).  The figure depicted is a 
middle-aged man or woman for whom ‘heart health’ is an identifiable concern, for 
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whom risks are a pertinent consideration, and who actively looks after their own health 
in recommended ways.     
 
FIGURE 4 HERE 
 
The story so far 
Before turning to the views of lay users and non-users of over the counter statins, we 
wish to draw attention to the fact that the diverse narratives discussed so far largely 
shared a belief that there would be a market for the product.   
 
These expectations, however, did not translate into sales. We have been unable to 
ascertain the overall size of the market.  Telephone conversations with more than 80 
pharmacists in high street pharmacies confirmed that sales of the product had been very 
low in 2010. We were also party to sales data from a major UK supermarket chain with 
more than one hundred pharmacies, in which mean sales for the year up to May 2007 
were just 8 packets per store3.  It is possible that online sales were higher.  Yet the 
product was quietly discontinued in September 2010, suggesting that the supermarket 
data did reflect the wider picture. 
 
So far, lay users, imagined as citizen-consumers, flawed or empowered consumers, have 
figured largely as implicated actors who have been discursively but not physically 
present (Clarke, 2005). In the final part of the analysis we turn to narratives from users 
or potential users of OTC statins, to explore the place of consumerism or consumer 
identities in their talk about cholesterol reduction. 
 
4. Lay narratives: consumerism in health?  
While statins have been widely used in the NHS for more than a decade (Department of 
Health, 2000), there is a longer history of commercial products and services linking to 
fears about cholesterol, from marketing for margarine and oat based cereals since the 
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1960s (Pollan, 2007) to pharmacy based cholesterol testing in the 1990s (Matthews, 
1993), and more recently functional foods such as margarines and yoghurt drinks 
containing phytosterols. Yet we were uncertain how far respondents might position 
themselves as ‘consumers’ in this field. In the following sections we discuss this issue 
with reference to talk about choices for cholesterol reduction and notions of 
responsibility for heart health. 
 
Pharmaceuticals as a commercial product 
Though professionals had been concerned that OTC statins would be too expensive and 
exclude many consumers, the small numbers of users we interviewed were likely to talk 
about them as good value considering the health benefits they expected. One told us 
that he had stopped buying phytosterol drinks because they were expensive and did not 
last well compared with the OTC product, another emphasized that the drugs were 
worth the money: 
 
 'Nine quid4 for a month’s supply so it wasn’t too bad really….  I was earning quite 
good money then so, and when you think about it in terms of you know am I 
going to live for another ten years longer you know it’s worth nine pounds a 
month isn’t it?' (Stat 44, ex OTC user since withdrawn) 
  
Purchase on the Internet was even cheaper, and allowed people to demonstrate further 
concern with value, presenting themselves as responsible consumers:  
 
'I went to the local pharmacy and when I found out how much they were I 
thought urgh that’s a bit expensive, am I even going to bother with doing this?  
But I had a look around on the Internet and I can actually buy, Zocor Heart Pro 
10mg… I can buy those on the Internet through a pharmacy in Scotland and I can 
get them at less than I would have to pay prescription charge' (Stat 21, OTC 
statins). 
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A market for those resisting drugs 
Looking to our wider set of interviews with users of functional foods and statins, it was 
clear that a broader market of cholesterol reduction technologies might also be 
accessed in efforts to avoid drugs. Stat 44, who had talked of the OTC drugs as good 
value, subsequently moved to purchasing both Benecol spread and a cheaper herbal 
remedy including phytosterols. Many other respondents talked about purchasing 
‘healthy’ foods (such as oats, nuts and seeds, fish, 'light' products and those with added 
phytosterols), vitamins and supplements and enrolling in commercial fitness and weight 
management programmes after a high cholesterol reading. Within this market again 
people might talk about looking for a low cost option:  
 
'My missus will probably get me what is on the best offer at that time.  Them 
drinks tend to fluctuate in price and there's deals on one week… But I do have a 
drink every day, but I wouldn’t say that it's Benecol all the time, like it can be 
anything.  You know if she goes to [supermarket] and the [own brand] ones are 
cheaper that week she may get the [supermarket] ones' (Phyt39, not on statins).  
 
A range of products, including phytosterols could be enrolled in efforts to avoid 
prescription statins offered by the doctor, narrated in terms familiar from the 
sociological literature on ‘resistance’ to medication, especially concerns about side 
effects or drug interactions.  
 
'The doctor wanted to put me on statins, but I don’t want to go on statins 
because of what I’ve read about the side-effects, so I said well give me 6 weeks 
to try and get it down and I joined slimming world and lost a stone and cut out 
[...]' (Phyt1, avoiding statins). 
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‘I suppose I would rather swallow the [yoghurt drink] bottle than a statin and a 
Q10 tablet you know, because I understand that pharmaceuticals that work very 
often do have some sort of side effects and after all you know I am taking other 
things.’  (Phyt30, avoiding statins). 
 
Our data also include examples of people trying pills and then coming off them, or 
hoping to reduce or come off in the future.  It was more common to assert that lifestyle 
change was used as a way to avoid pills than to admit to reducing lifestyle change 
because you were taking drugs – the scenario invoked in professional commentary (see 
Authors 2013 for fuller discussion). Our data thus show people exercising some 
consumer choices in a cholesterol market – looking for good value products and moving 
between functional and other foods, prescription and (sometimes) non-prescription 
pharmaceuticals. However while appearing quite active and reflexive in their approach 
to cholesterol reduction, most of our respondents did not describe themselves as 
entirely independent or self-reliant in this field. Interview talk intimated that they 
wished to share responsibility for cholesterol reduction with doctors or other 
professionals, who usually first raised the issue.  
 
The activated patient or primed consumer? 
For almost all our respondents, cholesterol emerged as a concern following some kind 
of clinical discussion, whether treatment for a separate medical condition or a health 
check. Contrary to the empowered consumers of marketing narratives, people did not 
describe themselves as starting with a desire to take control of their heart health, or 
generally seeking out risk assessments or cholesterol tests: 
 
Interviewer: so you said that I think you were first prescribed the statins some 
time in 2008, as a result of having the test, how did the blood test come about? 
Did you get called in or did you go into the doctors to ask for it? 
Phyt36: No I didn't, it was sort of coincidentally really.  I went in for something 
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quite different and the doctor does, you know a blood pressure monitor, and he 
found my blood pressure was high which wasn't normal and ordered a blood test 
as well, a general one, not specifically for this. And that's when I first discovered 
that I'd got the cholesterol. (formerly on prescription statins, rejected) 
 
Thus the identification of a problem with cholesterol for this woman in her late 70s had 
a feeling of ‘coincidental’ discovery.  She was offered prescription statins but stopped 
taking them after a few months because she experienced side-effects. As described 
above, she then turned to phytosterols as an alternative.  
 
Not only did people talk about cholesterol tests as initiated by health professionals, they 
also commonly suggested that professionals would lead on monitoring cholesterol. 
Though commercial home tests are now available, and pharmacy testing has been 
available for more than 20 years, respondents in both the phytosterol and prescription 
statin groups rarely sought to measure their cholesterol independently of their family 
doctor, though a few did make the appointment for follow up on their own initiative. 
Among our OTC users, two were self-monitoring and avoiding consultations with the 
doctor, but the rest were actively seeking conversations in general practice about 
cholesterol reduction. They tended to feel that they had been refused help for these 
problems, and ‘denied’ treatment. Thus the trajectory to using OTC statins was narrated 
not primarily in terms of choice or self-care, but with a sense that the doctor had not 
engaged with the question of what to do after a problematic cholesterol result. 
 
In a sense then, even those of our respondents who appeared initially as consumers of 
cholesterol reduction products presented themselves as seeking to share responsibility 
for cholesterol management. Our data place doubts on the idea that people are 
motivated to act alone around a notion of ‘heart health’, and to the extent that they 
make choices that involve them in cholesterol reduction, including purchasing 
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commercial products, they are perhaps best understood as ‘primed consumers’ or 
‘activated patients’.  
 
Claims on the state: the citizen-patient 
In contrast with the narratives of professionals, OTC users invoked the notion of 
inequality in describing themselves as being excluded from state-funded healthcare. In 
the case of one man in his 60s, the respondent was alerted to his potential raised 
cholesterol through an eye test, with his optician suggesting he get a cholesterol test.  
The respondent attended his doctors and was told that his cholesterol was high and 
continued to have this monitored by his doctor, but with nothing prescribed.  The 
respondent was aggrieved by this result, partly because he felt he deserved a reward for 
his good lifestyle and partly because of his awareness that others in a similar situation 
elsewhere had been prescribed statins on the NHS: 
  
'And they put, you’re scored on it, so as I said to my doctor, “So if I was fat, if I 
ate badly, smoked, didn’t exercise, so my health was really going downhill then 
you’d help me.… So I don’t know it just seems, I feel going back there and saying 
like I’ve started smoking, I’ve given up exercise can I have some statins? ... 
I have another friend whose cholesterol has never been as high as mine…His 
doctor prescribes him no problem. He’s very much the same as me, you know 
pretty fit, same age group, it’s just my particular surgery won’t give, I’m going to 
go back and see them, now I can’t [buy OTC statins]' (Stat 24, OTC statins) 
 
Even for this OTC user, who struck quite an independent attitude, statin taking was 
framed as part of a conversation with a doctor.  In this case, a sense of entitlement to 
the drugs was linked to the argument that the respondent had already made what 
lifestyle change he could as well as a sense that access to the treatment should be 
equitable across the NHS. Rather than acting in the mode of a citizen-consumer, making 
choices to take responsibility for their own health, some purchasers of OTC statins 
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appear as 'have nots', excluded from access to prescription statins (after Wyatt, 2005), 
and narrating this in the mode of the citizen-patient, in terms of entitlements to 
statutory health service on the basis of equality or merit. 
 
This narrative of entitlement found parallels in a small set of accounts from people who 
had been offered prescription statins but wanted to try ostensibly better but more 
expensive drugs within this class.  Again, respondents appeared to be acting in the mode 
of citizen-patients, narrating their entitlement with reference to their life-long 
contributions to the national purse or by making comparisons with those less deserving 
or less hard working.  
 
Discussion and conclusions 
In this paper we have narrated the story of OTC statins as one of high expectations from 
both policy and commercial sectors, and lack of enthusiasm from professionals and 
potential consumers. In policy, the statin reclassification appeared to fit with wider 
concerns to limit state support to those in greatest need, leaving ‘citizen-consumers’ 
(Clarke et al 2007) to make responsible choices in the space around these essential 
services. The marketing discussion also invoked the notion of choice as a rational and 
responsible action for those at risk. Most medical professionals and pharmacists also 
assumed that there would be a market for OTC statins, even as they invoked ‘flawed 
consumers’. Though these were not imagined to be the poor (c.f. Bauman) - who were 
excluded entirely – it was feared that people who could afford the product would make 
bad choices after purchase, like relying on drugs instead of making lifestyle changes, or 
taking too many or too few medications to see real benefit.  Interestingly these were the 
very arguments made in FDA hearings on a series of reclassification proposals in the USA 
(Tinetti, 2008).  
 
Comparing these ‘expectations’ of users with our interview data, we reported first on 
the very limited numbers of people who ever purchased OTC statins. This was not 
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because people refused to see themselves as consumers. Many of our respondents in 
both samples were purchasing a wide variety of products for heart health, making active 
choices between different foods and drugs on the basis of cost and convenience. 
However their focus was often cholesterol rather than the more abstract ‘risk’ that 
featured in OTC statin advertising. There was a market for cholesterol reduction, but the 
choices made in this market speak to continued resistance to the use of medication, as 
predicted by the work of Pound et al (2005) and others. Our 'resisting consumers' are, 
therefore, of a different sort to those identified by Fox (2006) who use pharmaceuticals 
in the context of their own explanatory frameworks and may reject medical models. In 
contrast, while biomedical models were largely accepted, over the counter statins were 
resisted – we found 'anything-but-pharmaceuticals' consumers. 
 
We suggest that for preventive medication at least, this resistance is still an important 
aspect of pharmaceutical consumerism, and goes a long way to explaining the failure of 
OTC statins in the UK. However we have also pointed to other reasons why the product 
struggled to find a market. Even when people accepted the idea of preventive 
medication, this acceptance almost always followed a cholesterol test. Such tests were 
most commonly done in the clinic and people continued to associate cholesterol 
management and monitoring with their general practitioner, not with pharmacists; 
these respondents continued to seek mediation for pharmaceutical use rather than act 
independently.  Our data supports the argument made by many that the language of 
consumption obscures patients’ preference for placing ‘trust’ in doctors (e.g. Lupton et 
al, 1991; MacDonald et al, 2007) and sharing responsibility for health decisions (e.g. 
Henwood, Wyatt, Hart and Smith 2003; Lupton 1997). Even when people started with 
commercial products, they might seek to get prescription statins subsequently. OTC 
users were not necessarily willing entrants to the pharmaceutical market, but 
sometimes bought statins grudgingly feeling excluded from statutory provision.  The 
preference for prescription statins seemed to be associated both with cost and a sense 
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of entitlement to care within a national health service, positioning users as ‘citizens’. 
This left little space for a ‘consumer’ account of their approach to pharmaceuticals.   
 
Though the literature on pharmaceuticalisation emphasises consumer demand and 
action, our data therefore suggest the continued importance of health care 
professionals both warranting drug use and advising on health.  In contrast to the 
notions of resisting consumers and expert or compliant patients, we have suggested the 
idea of the activated patient or the primed consumer, who may wish to take control of 
managing aspects of their health following their own rationales, but do so following 
professional prompting.  The concept draws attention to the chronology and process of 
'activeness'.  People do not appear in our data as simply one or other ‘type’ but rather 
take up particular positions within a continued clinical relationship. In our case study it 
appears to take certain sorts of interactions for patients/consumers to gain and sustain 
interest in cholesterol management and thus to consider medication.   
 
Given the failure of the OTC statin experiment, where the drugs did not sell, we suggest 
we should be cautious about assuming there will be a market for new drugs, especially 
in the area of prevention or risk reduction, when non-pharmaceutical products appear 
to offer solutions to the same problems, or when a social healthcare system offers 
cheaper prescription alternatives. As studies of ‘biological citizenship’ around the world 
suggest, a sense of entitlement to drugs can be established even in other healthcare 
systems around particular medical conditions such as HIV and AIDS.    
 
We end though with questions about the reclassification debates that keep re-emerging 
in the US context. The repeated failure of the companies to get approval for statin 
reclassification there is intriguing: there is already direct-to-consumer advertising and 
potential consumers may be more used to paying for medicines and more interested in 
avoiding the cost of health care consultations. However professional concerns about 
‘flawed consumers’ seem to have had greater weight in this context, perhaps partly 
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because they are not balanced by a state interested in limiting prescription costs. If 
statins are licensed for OTC sale in the future – and the proposals keep reappearing as 
prescription statins come off-patent – we will see if they sell there, or elsewhere.  
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1
 The individual consumer remains somewhat obscure in work on the expanding indications for drugs in 
Europe and the US (e.g. Greene 2007; Dumit 2012) though studies of global pharmaceuticals from 
anthropological perspective have lots to say about individuals in Brazil, Argentina, India and elsewhere 
(e.g. contributions to Petryna, Lakoff and Kleinman, 2006). 
2
 PCT: Primary Care Trust 
3
 One packet provides one month’s supply.  Average sales per store therefore equates to less than one 
person per store.  
4
 ‘Quid’ is a colloquial term for UK pounds sterling. 
